Clopidogrel: a case for indication-specific pharmacogenetics.

Johnson JA, Roden DM, Lesko LJ, Ashley E, Klein TE, Shuldiner AR
Clin Pharmacol Ther. 2012 91 (5): 774-6

PMID: 22513313 · PMCID: PMC3382015 · DOI:10.1038/clpt.2012.21

The CYP2C19*2 loss-of-function allele is associated with reduced generation of active metabolites of clopidogrel. However, meta-analyses have supported or discounted the impact of genotype on adverse cardiovascular outcomes during clopidogrel therapy, depending on studies included in the analysis. Here we review these data and conclude that evidence supports a differential effect of genotype on protection from major adverse cardiovascular outcomes following percutaneous coronary intervention (PCI), but not for other clopidogrel indications.

MeSH Terms (9)

Angioplasty, Balloon, Coronary Aryl Hydrocarbon Hydroxylases Clopidogrel Cytochrome P-450 CYP2C19 Genotype Humans Pharmacogenetics Platelet Aggregation Inhibitors Ticlopidine

Connections (1)

This publication is referenced by other Labnodes entities: